This website uses cookies

We use cookies to enhance your experience and support COUNTER Metrics for transparent reporting of readership statistics. Cookie data is not sold to third parties or used for marketing purposes.

Skip to main content
null
JHEOR
  • Menu
  • Articles
    • Author Correction
    • Autoimmune Diseases
    • Brief Report
    • Cardiovascular Conditions
    • Commentary
    • Correspondence
    • Dermatological Diseases
    • Endocrine Diseases
    • Gastrointestinal Conditions
    • General Indications
    • Genetic Disorders
    • Hematology
    • Infectious Diseases
    • Methodology and Healthcare Policy
    • Musculoskeletal Conditions
    • Nephrologic/Hepatologic Conditions
    • Neurological Disorders
    • Oncology
    • Ophthalmology
    • Other Conditions
    • Perspective
    • Psychological Conditions
    • Respiratory Diseases
    • Trauma Induced Conditions
    • Urological/Gynecological Diseases
    • All
  • For Authors
  • Editorial Board
  • About
  • Issues
  • Blog
  • Journal Policies
  • For Reviewers
  • search
  • X (formerly Twitter) (opens in a new tab)
  • Bluesky (opens in a new tab)
  • LinkedIn (opens in a new tab)
  • RSS feed (opens a modal with a link to feed)

RSS Feed

Enter the URL below into your favorite RSS reader.

http://localhost:58782/feed
ISSN 2327-2236
Methodology and Healthcare Policy
Vol. 1, Issue 3, 2014February 26, 2016 EDT

The Impacts of Breakthrough Drug Classes on Total Healthcare Expenditures

Zeynal Karaca, Steven N. Wiggins,
mepsprescription drugshealthcare expendituresdrug classes
Copyright Logoccby-4.0
Photo by Haley Lawrence on Unsplash
JHEOR
1.
Karaca Z, Wiggins SN. The Impacts of Breakthrough Drug Classes on Total Healthcare Expenditures. JHEOR. 2016;1(3):276-295.

View more stats

Powered by Scholastica, the modern academic journal management system